Adjuvant activity can be greatly improved by appropriate formulation of cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG ODNs).
Ryan C. Anderson
Advertisement
Ryan C. Anderson, formerly of the Infections Disease Research Institute, currently is the account consultant-northern California, at Chemical Abstracts Service
Articles by Ryan C. Anderson
Advertisement
Latest Updated Articles
Characterization of Aluminum Hydroxide Gel and Oil-in-Water Emulsion Formulations Containing CpG ODNsPublished: October 2nd 2010 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
